Recent Updates
Recently added Catalysts
XENE

Xenon to Report Q1 2026 Financial Results on May 7, 2026

Key Takeaway: VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for pat

Full Press Release Details

VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its first quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, May 7, 2026.
Company Presentation Details:
Date: Thursday, May 7, 2026
Time: 4:30pm ET (1:30pm PT)
Webcast: Pre-register here
Dial-In: (800) 715-9871 toll-free or (646) 307-1963 for international callers
Conference ID: 7898598
A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay following the event. The above-mentioned dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Chief Financial Officer
Senior Vice President, Corporate Affairs
Last updated: Apr 30, 2026